21 studies found for:    CAL101
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Conditions: Indolent Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma
Intervention: Drug: Idelalisib
2 Active, not recruiting Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Ofatumumab
3 Enrolling by invitation Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Idelalisib placebo
4 Active, not recruiting Phase 2 Safety and Efficacy Study of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: CAL-101
5 Active, not recruiting Efficacy and Safety Study of Idelalisib in Patients With Indolent B-Cell Non-Hodgkin Lymphoma
Conditions: Indolent Non-Hodgkin Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytoid Lymphoma;   Marginal Zone Lymphoma
Intervention: Drug: Idelalisib
6 Enrolling by invitation An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
Conditions: Chronic Lymphocytic Leukemia;   Lymphoma, Non-Hodgkin
Intervention: Drug: Idelalisib
7 Recruiting Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Fludarabine;   Drug: Everolimus;   Drug: Bortezomib;   Drug: Chlorambucil;   Drug: Lenalidomide
8 Recruiting A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL)
Interventions: Drug: Idelalisib;   Drug: Rituximab
9 Recruiting A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Placebo
10 Recruiting A Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Condition: Indolent Non-Hodgkin's Lymphomas
Interventions: Drug: idelalisib;   Drug: Rituximab;   Drug: Placebo
11 Recruiting A Study Evaluating the Efficacy and Safety of Idelalisib(GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Condition: Indolent Non-Hodgkin's Lymphomas
Interventions: Drug: Idelalisib orally 150 mg BID;   Drug: Placebo orally 150 mg BID;   Drug: Rituximab IV 375 mg/m2 every 28 days for 4 cycles;   Drug: Bendamustine 90 mg/m2 for 2 consecutive days every 28 days for 4 cycles
12 Active, not recruiting A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib + Rituximab;   Drug: Placebo + Rituximab
13 Withdrawn A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: GS-1101
14 Not yet recruiting Efficacy and Safety of Idelalisib in Combination With Rituximab or Chlorambucil for Previously Untreated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Chlorambucil;   Drug: Idelalisib placebo
15 Recruiting Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Bendamustine;   Drug: Rituximab;   Drug: Idelalisib placebo
16 Active, not recruiting A Phase 2 of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Conditions: Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma;   Diffuse Large B-cell Lymphoma;   Indolent Non-Hodgkin's Lymphoma
Interventions: Drug: GS-9973;   Drug: Idelalisib
17 Completed Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
Condition: Allergic Rhinitis
Interventions: Drug: CAL-101;   Drug: Placebo
18 Not yet recruiting Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Condition: B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
Interventions: Drug: Idelalisib;   Drug: Rituximab
19 Recruiting Lenalidomide and Rituximab With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Relapsed/Refractory Mantle Cell Lymphoma
Interventions: Drug: lenalidomide;   Drug: idelalisib;   Biological: rituximab
20 Completed Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
Conditions: Chronic Lymphocytic Leukemia (CLL);   Lymphoma, Non-Hodgkin (NHL);   Acute Myeloid Leukemia (AML);   Multiple Myeloma (MM)
Intervention: Drug: CAL-101

Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results
Indicates status has not been verified in more than two years